Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves necitumumab for non-small cell lung cancer

Necitumumab (Eli Lilly’s Portrazza) has been approved by the US drugs safety watchdog for patients with advanced squamous non-small cell lung cancer (NSCLC), image attached, who have not received other treatment for their advanced disease

Source: Nephron / Wikimedia Commons

Patients with squamous non-small cell lung cancer in the United States have a new treatment option after the approval of necitumumab by the FDA

Necitumumab (Eli Lilly’s Portrazza) has been approved by the US drugs safety watchdog for patients with advanced squamous non-small cell lung cancer (NSCLC) who have not received other treatment for their advanced disease. It is approved for use in combination with gemcitabine and cisplatin.

The decision by the US Food and Drug Administration (FDA) follows the results of a multi-centre randomised clinical trial involving 1,093 patients with the disease.

The patients were given gemcitabine and cisplatin with or without necitumumab. Those taking necitumumab plus gemcitabine and cisplatin lived longer on average than those who only took gemcitabine and cisplatin (11.5 months versus 9.9 months, respectively). Necitumumab, a monoclonal antibody that blocks the activity of EGFR, was not an effective treatment in patients with non-squamous NSCLC.

“Lung cancer tumours can be varied, so treatment options need to be tailored to the specific type of lung cancer in the patient,” says Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The approval provides certain patients with squamous cell lung cancer a new option that may extend survival.”

The FDA has, however, given the product a black box warning because of its serious side effects, including cardiac arrest and magnesium deficiency, which can cause muscle weakness, seizure, irregular heartbeats and which can be fatal.

The product is not currently marketed in the European Union, according to the database of the European Medicines Agency.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200197

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Necitumumab (Eli Lilly’s Portrazza) has been approved by the US drugs safety watchdog for patients with advanced squamous non-small cell lung cancer (NSCLC), image attached, who have not received other treatment for their advanced disease

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.